Sign in

    Joe Schwartz

    Managing Director and Senior Biotechnology Analyst at Leerink Partners

    Joe Schwartz is a Managing Director and Senior Biotechnology Analyst at Leerink Partners, specializing in equity research across the biotechnology landscape with a particular focus on rare disease companies such as Amicus Therapeutics, Design Therapeutics, and others. He has been recognized for his performance, earning prestigious industry awards including #1 Stock Picker for Pharmaceuticals in the 2011 FT/StarMine Analyst Awards and the Wall Street Journal’s #1 ranking for biotech stock picking in 2010. Schwartz began his finance career with consulting roles at Charles River Associates, and held prior analyst positions at JP Morgan, SG Cowen, and State Street Research before joining Leerink in 2003. He holds an MBA from Babson College and a BA in Economics from Colby College, and is a registered securities professional with extensive experience in biotechnology equity research.

    Joe Schwartz's questions to Wave Life Sciences (WVE) leadership

    Joe Schwartz's questions to Wave Life Sciences (WVE) leadership • Q3 2024

    Question

    Jenny, on for Joe Schwartz of Leerink Partners, asked about the WVE-006 RNA editing program, seeking to confirm if the 60% M-AAT protein level suggests editing efficiency could still increase, if Wave is at the bottom of the dose curve, and how much higher the dosage could go.

    Answer

    CEO Paul Bolno confirmed that achieving 60% M-protein with the lowest single dose is a very encouraging surrogate for editing efficiency and that they are at the low end of the dose curve. He expects efficiency to increase with repeat dosing, based on preclinical data. He also stated they have ample room to increase the dose, are already dosing higher in healthy volunteers, can dose higher than inclisiran, and will also explore extending the dosing interval for less frequent administration.

    Ask Fintool Equity Research AI

    Joe Schwartz's questions to Protagonist Therapeutics (PTGX) leadership

    Joe Schwartz's questions to Protagonist Therapeutics (PTGX) leadership • Q1 2020

    Question

    Joe Schwartz from SVB Leerink asked about any notable changes in other blood components like leukocytes and platelets, the timeline for the next data updates from the current trial, how quickly a pivotal trial could begin, and what the design and endpoints of such a trial might look like.

    Answer

    Dr. Ronald Hoffman referred to appendix slides showing that leukocyte and platelet counts remained steady during treatment. Chief Medical Officer Dr. Samuel Saks explained that the company is currently working with thought leaders to design the pivotal study and will discuss it with the FDA once finalized, with further data updates expected in the second half of the year. President and CEO Dinesh Patel added that enrollment is strong and the company intends to share more data as it is gathered from the expanded study.

    Ask Fintool Equity Research AI